SOUTH SAN FRANCISCO, Calif. and ANN ARBOR, Mich., June 22, 2021 (GLOBE NEWSWIRE) — Tempest Therapeutics a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics announced today the results for the proposals voted upon by Millendo stockholders at a Special Meeting on June 22, 2021. The stockholders voted in favor of all proposals at the Special Meeting, including to approve the proposed merger between the companies.
The closing of the merger is anticipated to take place on or around Friday, June 25, 2021. Following the closing of the merger, the combined company will be renamed Tempest Therapeutics and shares will begin trading with the open of the market on Monday, June 28, 2021 under the ticker “TPST.”
About Millendo Therapeutics.
Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. For more information, please visit www.millendo.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to control activation of the cGAS/STING pathway, an innate immune response pathway involved in the development of anti-tumor immunity. Tempest is headquartered in South San Francisco and supported by notable healthcare investors. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Millendo Investor Contact:
Lou Arcudi
617-909-0333
arcudi@millendo.com
Millendo Media Contact:
Julie Bane
MacDougall
617-821-1089
jbane@macbiocom.com
Tempest Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Alex Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com